Phase III results from RISE-PD clinical study of IPX 203

Recently, Amneal Pharmaceuticals announced that the FDA has accepted for review the New Drug Application for IPX203 for the treatment of

IPX-203 was intended to be a modification of carbidopa and levodopa, a well-known combination treatment for Parkinson's disease (CX1209 at 003;

ipx916 IPX203-00005 and IPX203-C0006 in comparison with Sinemet® CR All the IPX 203 multi-particulate formulations comprise Eudragit® E coating The relative

ipx794 203 Impax and Endo agreed to share promotional responsibilities for IPX